Carcinoid Tumor

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-based Analysis 2000-2022

A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022

The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

ALG-LungCancerRegistry (SAFRO2202)

Cabozantinib and Nivolumab for Carcinoid Tumors

The Registry of Oncology Outcomes Associated with Testing and Treatment

Personalized PRRT of Neuroendocrine Tumors

Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors